Research

Please find below articles from Portuguese authors and co-authors that were published in the European Journal of Neurology

The celebrations of the Dystonia Europe 25th annniversary kicked off with a special lunch event in the European Parliament on 12 April. The 65 guests were welcomed by the Finnish Member of the European Parliament (MEP) Ms. Merja Kyllönen.  She… Continue Reading

Please find below articles from Belarusan authors and co-authors that were published in the European Journal of Neurology

For May 2018, we have selected: Kappos L, Bar-Or A, Cree BAC, et al., for the EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet Neurol 2018;391:1263-1273. Secondary progressive multiple sclerosis (SPMS) is characterized by a previous history of relapsing remitting MS (RRMS) and the continuous progression of disability over the years typically without relapses.

Please find below articles from French authors and co-authors that were published in the European Journal of Neurology

For April 2018, we have selected: Whelan CD, Altmann A, Botia JA, et al., for the ENIGMA-Epilepsy Working Group. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain 2018;141:391-408. Epilepsy affects 0.6-1.5% of the population worldwide with one-third of patients being resistant to antiepileptic treatment. Nowadays epilepsy is considered a network disorder in which several structural changes are involved.

by Prof. Radu Tanasescu   Paper: Maggi et al. ‘Central Vein Sign Differentiates Multiple Sclerosis from Central Nervous System Inflammatory Vasculopathies’. Annals of Neurology. 2018;83:283–294. Outline: This paper shows for the first time that central vein assessment in white matter… Continue Reading

Epilepsy Center, Neurocenter, Kuopio University Hospital and Faculty of Health Sciences, School of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland

by Elena Moro For March 2018, we have selected: Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 2018;378:321-330. Alzheimer’s disease (AD) pathology can be related to either excessive production or reduced elimination of beta amyloid (Aβ), which eventually results in oligomers, fibrils, and neuritic Aβ plaques.

Antonio Federico (AF): On January 29-30, there has been in Tubingen the Kick-Off Meeting of the EU Project Solve-RD. You and Prof. Olaf Riess are coordinating this project. Can you summarize the aim and the activities of this important project? Holm Graessner (HG): To obtain a molecularly confirmed diagnosis remains one of the largest challenges for rare disease patients. To jointly tackle this challenge a core group of four European Reference Networks including the European Reference Network for Rare Neurological Diseases has motivated, designed and put together the Solve-RD project which is the first ERN based H2020 funded research project. Solve-RD brings together 21 partners from 10 countries which will be running from 2018 to 2022.

It is our great pleasure to announce the 2nd edition of the EAN Task Force for Rare Neurologic Diseases Teaching Course, to be organized in Cluj-Napoca (Romania), from 5-7 September 2018. As last year’s event was a success, the Task… Continue Reading